Potentiation by previous nutrients of glibenclamide-induced insulin release in man. An effect which is counteracted by meal-induced retardation of drug absorption
- PMID: 3095909
- DOI: 10.3109/00365518609083708
Potentiation by previous nutrients of glibenclamide-induced insulin release in man. An effect which is counteracted by meal-induced retardation of drug absorption
Abstract
We have studied the impact of a previous meal on insulin and glucose responses to the subsequent administration of glibenclamide. Healthy volunteers and NIDDM patients ingested a standard low-carbohydrate breakfast, and glibenclamide was administered 110-120 min later either as an intravenous bolus (12.5 micrograms/kg body wt), or as a tablet (5 mg HB 419). When glibenclamide was administered i.v. the drug raised insulin and lowered blood glucose levels, and previous breakfast potentiated these effects both in healthy volunteers and in NIDDM patients. Conversely when glibenclamide was given as a tablet the drug per se raised C-peptide and lowered blood glucose levels under fasting conditions, whereas the drug had no effect when ingested after breakfast. Measurements of glibenclamide in plasma revealed that previous breakfast delayed the systemic appearance of ingested glibenclamide. We conclude that nutrients sensitize insulin-releasing cells to subsequent stimulation by glibenclamide, thereby aggravate a blood-glucose-lowering effect of the drug. However this effect, which could potentially induce undesirable hypoglycaemia in sulphonylurea-treated diabetics, is counteracted when glibenclamide is taken orally because of a meal-induced decrease in drug absorption.
Similar articles
-
Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.Diabetes Care. 1996 Aug;19(8):857-63. doi: 10.2337/diacare.19.8.857. Diabetes Care. 1996. PMID: 8842604 Clinical Trial.
-
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.Diabet Med. 1996 Sep;13(9 Suppl 6):S151-5. Diabet Med. 1996. PMID: 8894500 Review.
-
The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.Diabetes Nutr Metab. 2002 Jun;15(3):143-51. Diabetes Nutr Metab. 2002. PMID: 12173728 Clinical Trial.
-
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.Horm Metab Res. 1996 Sep;28(9):445-50. doi: 10.1055/s-2007-979835. Horm Metab Res. 1996. PMID: 8911981 Clinical Trial.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.Clin Pharmacokinet. 1989 Feb;16(2):100-28. doi: 10.2165/00003088-198916020-00004. Clin Pharmacokinet. 1989. PMID: 2656043 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical